Placeholder Banner

BIO Submits Comments on Medicare CY 2020 Part D Draft Call Letter

March 20, 2019

BIO submitted comments on the Centers for Medicare and Medicaid Service’s Advance Notice of Methodological Changes for Calendar Year (CY) 2020 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2020 Draft Call Letter.

BIO supports CMS’s commitment to improving the quality and delivery of care in the MA and Part D programs. It’s critically important to ensure these programs advance patient access to timely and appropriate treatment, particularly for prescription drugs and vaccines. BIO provided comments on how to update and clarify the policies and provide greater access to patients while mitigating OOP costs.

Download Full Comments Below
FINAL BIO CY 2020 Draft Call Letter Comments 1 March 2019
See the full comment letter here:
Discover More
Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the opportunity to submit comments on the “Draft Guidance: Nonclinical Safety Evaluation of the Immunotoxic Potential of…
April 12, 2020   Re: Docket No. FDA–2019-D-5585: FDA Draft Guidance, Bridging for Drug-Device and Biologic-Device Combination Products.   Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug…
March 18, 2020 FDA Docket No: FDA-2019-D-4964: FDA Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Dear Sir/Madam: BIO thanks FDA for developing this additional guidance on…